Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition

Xiong, Gaofeng; Deng, Lan; Zhu, Jieqing; Rychahou, Piotr G.; Xu, Ren

doi:10.1186/1471-2407-14-1

Cited by 530 publications

(434 citation statements)

References 55 publications

Supporting

Mentioning

398

Contrasting

Unclassified

Order By: Relevance

“…We also found five of these proteins exclusively with TRIzol© extraction and seven exclusively using Laemmli extraction (Supplemental File #1). Comparisons with the EV proteins identified by Kruger [25] from MDA-MB-231 EVs showed that we identified 28 of 88 reported proteins (Supplemental File#1). From the top 25 proteins listed in Exocarta, 16 proteins were identified using both extraction methods, while a single hit was exclusive to Laemmli extraction (Table 1).…”

Section: Resultsmentioning

confidence: 81%

“…Three publications have reported specifically on proteins identified in MCF-7 EVs [23–25]. Additionally, based on the results from 59 cancer cell lines, Hurwitz [23] compiled a list of 213 proteins with unique gene symbols found to be common to multiple cancer cell lines, including MCF-7.…”

Section: Resultsmentioning

confidence: 99%

“…Staubach [24] reported 28 proteins from EVs of MCF-7 cells, of which we observed 16 using both extraction methods and just one unique match for Laemmli extraction (Supplemental File#1). Finally, Kruger [25] tabulated a total of 59 EV proteins from MCF-7 cells, of which we identified 26 using both protein-extraction methods and one exclusively with TRIzol© (Supplemental File #1). Comparison of our MCF-7 dataset with the top 200 proteins listed by EVpedia shows that we identified 121 matching proteins, where four are unique to Laemmli extraction, and one is exclusive to TRIzol© extraction (Supplemental File #1).…”

Section: Resultsmentioning

confidence: 99%

“…Hurwitz [23], Kruger [25] and Palazzolo [2] have each published lists of proteins identified from EVs produced by MDA-MB-231 cells. Compared with the 213 EV proteins listed by Hurwitz [23], we identify a total of 105 proteins in common with 72 matches for both extraction methods, seven matches unique to Laemmli extraction and 26 matches exclusively with TRIzol© extraction (Supplemental File#1).…”

Section: Resultsmentioning

confidence: 99%

“…We compared our datasets with published lists of EV proteins that have been identified as both common and cell-type specific. For these analyses, we used two databases that provide lists of common EV proteins, Exocarta (exocarta.org) and EVpedia (student4.postech.ac.kr/evpedia2_xe/xe/), as well as publications that report specifically on the proteins present in MCF-7 [23–25] and MDA-MB-231 EVs [2,23,25]. These comparisons demonstrate that using our Vn96/LC-MS/MS workflow we have identified EV proteins that are congruent to those reported in other studies, but we also determined via nanoLC-MS/MS that our EV isolation and protein-extraction platform identifies unique sets of EV proteins.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Proteome profiling of extracellular vesicles captured with the affinity peptide Vn96: comparison of Laemmli and TRIzol© protein‐extraction methods

Joy

Ayre

Chute

et al. 2018

J of Extracellular Vesicle

View full text Add to dashboard Cite

Sample amount is often a limiting factor for multi-parametric analyses that encompass at least three areas of ‘-omics’ research: genomics, transcriptomics and proteomics. Limited sample amounts are also an important consideration when these multi-parametric analyses are performed on extracellular vesicles (EVs), as the amount of EVs (and EV cargo) that can be isolated is often very low. It is well understood that a monophasic solution of phenol and guanidine isothiocyanate (i.e. TRIzol©) can simultaneously isolate DNA, RNA and proteins from biological samples; however, it is most commonly used for the extraction of RNA. Validation of this reagent for the isolation of multiple classes of biological molecules from EVs would provide a widely applicable method for performing multi-parametric analyses of EV material. In this report, we describe a comparison of proteins identified from EVs processed with either TRIzol© or the conventional Laemmli buffer protein-extraction reagents. EVs were isolated from 3 mL of cell-culture supernatant derived from MCF-10A, MCF-7 and MDA-MB-231 cells using the Vn96 EV capture technology. For the TRIzol© extraction protocol, proteins were precipitated with acetone from the organic phase and then re-solubilized in a mixture of 8M urea, 0.2% SDS and 1 M Tris-HCl pH 6.8, followed by dilution in 5× loading buffer prior to fractionation with 1D SDS-PAGE. NanoLC-MS/MS of the trypsin-digested proteins was used to generate proteomic profiles from EV protein samples extracted with each method. Of the identified proteins, 57.7%, 69.2% and 57.0% were common to both extraction methods for EVs from MCF-10A, MCF-7 and MDA-MB-231, respectively. Our results suggest that TRIzol© extraction of proteins from EVs has significant equivalence to the traditional Laemmli method. The advantage of using TRIzol© reagent is the ability to accumulate multi-parametric data (e.g., RNA and protein profiles) on the same limited EV sample while minimizing sample preparation and processing time.

show abstract

Section: Resultsmentioning

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Proteome profiling of extracellular vesicles captured with the affinity peptide Vn96: comparison of Laemmli and TRIzol© protein‐extraction methods

Joy

Ayre

Chute

et al. 2018

J of Extracellular Vesicle

View full text Add to dashboard Cite

show abstract

A Sequential Dual Functional Supramolecular Hydrogel with Promoted Drug Release to Scavenge ROS and Stabilize HIF‐1α for Myocardial Infarction Treatment

Wang,

Yao,

Wang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Myocardial infarction (MI) has a characteristic inflammatory microenvironment due to the overproduction of reactive oxygen species (ROS), and causes the extraordinary deposition of collagen and thereby fibrosis. An on‐demand adaptive drug releasing hydrogel was designed to modulate the inflammatory microenvironment and inhibit cardiac fibroblasts (CFs) proliferation post MI by scavenging the overproduced ROS and releasing 1,4‐dihydrophenonthrolin‐4‐one‐3‐carboxylic acid (DPCA) to maintain the expression of hypoxia‐inducible factor 1α (HIF‐1α). DPCA was prefabricated to a prodrug linked with disulfide bond (DPCA‐S‐S‐OH). The DPCA‐S‐S‐OH and carboxylated calixarene (CSAC4A) were grafted onto the backbone of methacrylated hyaluronic acid (HAMA) to obtain HAMA‐S‐S‐DPCA and HAMA‐CA, respectively, which were further reacted to form a dual network hydrogel (R+/DPCA(CA)) with covalent linking and host‐guest interaction between DPCA and CSAC4A. The ROS‐triggered hydrolysis of ester bond and subsequently sustaining release of DPCA from the cavity of CSAC4A jointly caused the constant expression of HIF‐1α, which significantly restricted the CFs proliferation, leading to suppressed fibrosis and promoted heart repair.This article is protected by copyright. All rights reserved

show abstract

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

et al. 2017

View full text Add to dashboard Cite

Radiation therapy (RT) including external beam radiotherapy (EBRT) and internal radioisotope therapy (RIT) has been widely used for clinical cancer treatment. However, owing to the low radiation absorption of tumors, high doses of ionizing radiations are often needed during RT, leading to severe damages to normal tissues adjacent to tumors. Meanwhile, the RT efficacies are limited by different mechanisms, among which the tumor hypoxia-associated radiation resistance is a well-known one, as there exists hypoxia inside most solid tumors while oxygen is essential to enhance radiation-induced DNA damages. With the development in nanotechnology, there have been great interests in using nanomedicine strategies to enhance radiation responses of tumors. Nanomaterials containing high-Z elements to absorb radiation rays (e.g. X-ray) can act as radio-sensitizers to deposit radiation energy within tumors and promote treatment efficacy. Nanoscale carriers are able to deliver therapeutic radioisotopes into tumors for internal RIT, or chemotherapeutic drugs for synergistically combined chemo-radiotherapy. As uncovered in recent studies, the tumor microenvironment could be modulated by various nanomedicine approaches to overcome hypoxia-associated radiation resistance. Herein, the authors will summarize the applications of nanomedicine for RT cancer treatment, and pay particular attention to the latest development of 'advanced materials' for enhanced cancer RT.

show abstract

Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition

Cited by 530 publications

References 55 publications

Proteome profiling of extracellular vesicles captured with the affinity peptide Vn96: comparison of Laemmli and TRIzol© protein‐extraction methods

Proteome profiling of extracellular vesicles captured with the affinity peptide Vn96: comparison of Laemmli and TRIzol© protein‐extraction methods

A Sequential Dual Functional Supramolecular Hydrogel with Promoted Drug Release to Scavenge ROS and Stabilize HIF‐1α for Myocardial Infarction Treatment

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

Contact Info

Product

Resources

About